Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...
But what if one of them encounters significant competition soon? That's what some investors believe might happen, given ...
Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.
Boehringer Ingelheim has put up 407.5 million euros ($478 million) in biobucks to secure global rights to a first‑in‑class ...
An expert from Northway Biotech and Lithuania’s Minister of Economy and Innovation talk about how the country is poised to be ...
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately ...
Biotech stocks are gaining momentum on M&A activity, cancer drug launches and upcoming autoimmune treatment data.
The company is recognized for its innovation, scientific expertise, and customer-centric clinical development model in the global biotechnology CRO market ...
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrie ...
Some proposed clinical trial rules could create hurdles for smaller countries while failing to ensure high quality and ...
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451Continued ...
Bayer has removed a protein therapeutic for hypertension and a treatment for diabetic neuropathic pain from its phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results